Ahmed Kotb on X: "🧠Mantle Cell Lymphoma– ESMO 2025 🔬Test TP53+→ Clinical trials 🟢Asymptomatic/limited stage → Observe or treat if risk factors 🔵Symptomatic, fit →R-CHOP/R-DHAP ±Ibrutinib→ ASCT→R maintenance 🧓Unfit/older →BR, VR-CAP, R-BAC or BTKi-based ± R maintenance #MCL #Lymphoma https://t.co/itDMmVpaiR" / X

Meral Beksac on X: "As a participant of DREAMM-8 all our patients in the experimental arm are still in CR w alternate cycle/ dose modifications of Belamaf unlike the control arm. A highly efficaous Rx with manageable ocular toxicity" / X

Vincent Rajkumar on X: "Just out! Latest NCCN guidelines has added daratumumab as Category 1 recommendation for high risk smoldering myeloma. In AQUILA trial, daratumumab: -Delayed progression to active myeloma -Delayed time to needing full myeloma therapy -Better overall survival https://t.co/nLqNX85XOZ" / X

R-DA-EPOCH versus DA-EPOCH-R: Impact of Chemoimmunotherapy Sequencing on Treatment Outcomes in Patients with Diffuse Large B-cell Lymphoma

CD99 expression in acute myeloid leukemia with FLT3 internal tandem duplications (FLT3-ITDmut-AML): a flow-cytometric marker for an accurate diagnostic workup

Haematologica on X: "A new review series on myeloproliferative neoplasms: prevention, diagnosis and management. A selection of a few key topics of particular interest due to recent advances in basic or clinical research. https://t.co/XCVKkYsBUX https://t.co/qihWb5dKPA" / X